Abstract

This is a revised application to establish the University of Colorado Health Sciences Center for AIDS Research (Colorado CFAR). The proposed Colorado CFAR is a collaborative effort of HIV/AIDS investigators from the University of Colorado Health Sciences Center and its affiliated institutions. The University of Colorado and its affiliated institutions constitute the only comprehensive AIDS research center between St. Louis and California. The proposed CFAR will provide a unique synthesis of basic, translational and clinical research with public health and AIDS prevention programs. The goals of the University of Colorado CFAR are to provide scientific leadership and stimulate scientific collaboration among AIDS investigators by providing institutional infrastructure and promoting scientific communication across disciplines. In addition the CFAR will promote opportunities for training and education in AIDS research, as well as the dissemination of knowledge to the scientific community and to the community at large. Specific cores proposed for this CFAR include Development, Clinical, Virology, Immunology, and SCID-hu cores.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI054907-05
Application #
7237335
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
2003-05-15
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2010-04-30
Support Year
5
Fiscal Year
2007
Total Cost
$1,588,725
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Cook, Paul F; McElwain, Catherine J; Bradley-Springer, Lucy A (2016) Brief report on ecological momentary assessment: everyday states predict HIV prevention behaviors. BMC Res Notes 9:9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Haas, Michelle K; Levy, David N; Folkvord, Joy M et al. (2015) Distinct patterns of Bcl-2 expression occur in R5- and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo. AIDS Res Hum Retroviruses 31:298-304
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085

Showing the most recent 10 out of 95 publications